We carried out an observational study to analyze if the quality of life of T1DM patients is affected by different insulin treatment systems. The study involved 113 T1DM patients from a public diabetes center, mean age 32.61(±12.59) years, 46% male treated with MDI or CSII. The Insulin System Rating Questionnaire (IDSRQ) was validated in Brazilian Portuguese (Table 1) and was self-completed by the subjects during a routine visit. Multiple comparison analysis (Table 2) showed that CSII had a significant effect versus syringe and versus pen for treatment satisfaction and clinical efficacy domains. CSII was associated with a higher treatment satisfaction and patient’s perception of better clinical efficacy than MDI.
R.C.L. Coelho: None. A.S. Pagano: None. A.N. Soares: None. J.S. Reis: None.
